Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors
1. 系统已在2026-07-06 11:25:13对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-25-02444
文献链接: https://ascopubs.org/doi/10.1200/JCO-25-02444
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Maria Vieito; Elisa Fontana; Catherine H. Han; Eduardo Castanon; David J. Pinato; Oliver Bechter; Rikke L. Eefsen; Irene Moreno; Hans Prenen; Reinhard Dummer; Ruth Plummer; Gabriel Schnetzler; Martin Kornacker; Piergiorgio Pettazzoni; Florian Renner; Mahdi About; Martha L. Serrano-Serrano; Christina Godfried Sie; Abiraj Keelara; Andreas Roller; David Dejardin; Elisa Cinato; Tomi Fakolade; Ernesto Guarin; Nick Flinn; Nicole A. Kratochwil; Nino Keshelava
